EMT inhibitor-1 NEW
| Price | $113 | $278 | $446 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-06-11 |
Product Details
| Product Name: EMT inhibitor-1 | CAS No.: 1638526-21-2 |
| Purity: 99% | Supply Ability: 10g |
| Release date: 2025/06/11 |
Product Introduction
Bioactivity
| Name | EMT inhibitor-1 |
| Description | EMT inhibitor-1 is a compound that inhibits Hippo and Wnt signaling pathways, as well as TGF- macrophages (TGF-), exhibiting antitumor activity. |
| In vitro | EMT inhibitor-1 (C19) inhibiting cancer cell migration, proliferation, and resistance to doxorubicin in vitro.EMT inhibitor-1 (C19) (0-10μM; 24 hours) is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities[1]. |
| In vivo | EMT inhibitor-1 (C19) (intraperitoneal injection; 5-20 mg/kg) demonstrates significant antitumor activity in a mouse tumor model. Mechanistically, it induces GSK3-β–mediated degradation of the Hippo transducer TAZ through activation of the Hippo kinases Mst/Lats and the tumor suppressor kinase AMPK, which are upstream of the degradation complex. C19 is dissolved in the vehicle solution (100 μL of DMEM containing 5% dimethyl sulfoxide) [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 90 mg/mL (281.95 mM), Sonication is recommended. |
| Keywords | βcatenin | Wnt/β-catenin | Wnt/betacatenin | Wnt/b-catenin | Wnt | EMT inhibitor-1 | EMT inhibitor1 | EMT inhibitor 1 | beta-catenin | betacatenin | bcatenin |
| Inhibitors Related | Urea | PRI-724 | Wnt pathway activator 1 | TNIK-IN-3 | L-quebrachitol | CHIR-99021 | XAV-939 | HLY78 | TNIK-IN-2 | Nefopam hydrochloride | KY-05009 | Bisdemethoxycurcumin |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Cancer Cell Differentiation Compound Library | Anti-Cancer Metabolism Compound Library | Neuroprotective Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Liver Cancer Compound Library | Anti-Cancer Active Compound Library | Neuronal Differentiation Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2820.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $5.00/1BOX |
VIP1Y
|
Hebei Jiafan Trading Company Limited
|
2025-05-14 | |
| $113.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-06-11 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY